GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q4 FY23 results · Jan–Mar 2023
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹787.45 crore (down 2.7% from Q4 FY22) and net profit of ₹133.43 crore (down 89.1% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 787.45 | 809.63 | −2.7% | 802.30 | −1.9% |
| Other income | 27.66 | 18.76 | +47.4% | 23.42 | +18.1% |
| Total income | 815.11 | 828.39 | −1.6% | 825.72 | −1.3% |
| Profit before tax | 189.97 | 207.85 | −8.6% | 224.25 | −15.3% |
| Net profit for the period | 133.43 | 1,219.05 | −89.1% | 164.56 | −18.9% |
| EPS, basic (₹) | 7.88 | 71.96 | −89.0% | 9.71 | −18.8% |
| Net margin (%) | 16.9 | 150.6 | 20.5 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 782.16 | 791.92 | −1.2% | 799.11 | −2.1% |
| Other income | 27.97 | 18.94 | +47.7% | 23.60 | +18.5% |
| Total income | 810.13 | 810.86 | −0.1% | 822.71 | −1.5% |
| Profit before tax | 187.30 | 206.24 | −9.2% | 223.53 | −16.2% |
| Net profit for the period | 131.48 | 1,217.84 | −89.2% | 164.03 | −19.8% |
| EPS, basic (₹) | 7.77 | 71.89 | −89.2% | 9.68 | −19.7% |
| Net margin (%) | 16.8 | 153.8 | 20.5 |
Consolidated
- Filed with BSE
- 18 May 2023, 17:36 IST
- Board meeting
- 17 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2023, 17:36 IST
- Board meeting
- 17 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE